中国临床医学2012，Vol.19Issue(6)：611-612,2.
多西他赛联合顺铂治疗晚期胸腺癌的疗效
Efficacy of Docetaxel Combined with Cisplatin in the Treatment of Advanced Thymic Carcinoma
赵怡卓 1隋丹 1朱蕾 1姜丽岩1
作者信息
- 1. 上海交通大学附属胸科医院肺内科,上海200030
- 折叠
摘要
Abstract
Objective:To analyze the efficacy of docetaxel combined with cisplatin in advanced thymic carcinoma. Methods; Clinical data of 70 patients with advanced thymic carcinoma confirmed by pathology from Jan 2007 to Nov 2011 was retrospectively analyzed. The patients in observation group(n = 35) were treated by docetaxel combined with cisplatin, and the patients in control group(n = 35) were treated by other chemotherapy methods. Four weeks was taken as a cycle , and patients had at least 2 cycles of chemotherapy in both groups. Results: The response rates (RR) in observation group and control group were 48. 6% and 25. 7% respectively; the disease control rates (DCR) were 85. 7% and 74. 2% , respectively; and there was significant difference between the two groups(P<0. 05). The progression free survival(PFS) in observation group and control group were 17 months and 11 months; and the overall survival(OS) were 35 months and 27 months, respectively (P＞0.05). Multi-variate Cox regression analysis showed that staging and treatment methods were important prognostic factors. Conclusions: Docetaxel combined with cisplatin in the treatment of advanced thymic carcinoma has better efficacy than other chemotherapy. The multidisciplinary treatment can prolong survival time of patients with advanced thymic carcinoma.关键词
胸腺癌/化疗/预后Key words
Thymic carcinoma/ Chemotherapy/ Prognosis分类
医药卫生引用本文复制引用
赵怡卓,隋丹,朱蕾,姜丽岩..多西他赛联合顺铂治疗晚期胸腺癌的疗效[J].中国临床医学,2012,19(6):611-612,2.
